Skip to main content
Edward Ball, MD, Oncology, San Diego, CA

EdwardDBallMD

Oncology San Diego, CA

Professor of Hematology & Oncology, UCSD

Dr. Ball is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Ball's full profile

Already have an account?

  • Office

    200 W Arbor Dr
    San Diego, CA 92103
    Phone+1 800-926-8273

Education & Training

  • Dartmouth-Hitchcock/Mary Hitchcock Memorial Hospital
    Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Hematology and Medical Oncology, 1982 - 1983
  • Case Western Reserve University/University Hospitals Cleveland Medical Center
    Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 1979 - 1981
  • University of Connecticut
    University of ConnecticutResidency, Internal Medicine, 1976 - 1979
  • Case Western Reserve University School of Medicine
    Case Western Reserve University School of MedicineClass of 1976

Certifications & Licensure

  • NH State Medical License
    NH State Medical License 1982 - Present
  • CA State Medical License
    CA State Medical License 1998 - 2026
  • PA State Medical License
    PA State Medical License 1991 - 1998
  • OH State Medical License
    OH State Medical License 1979 - 1982
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
  • Elected Member The American Society for Clinical Investigation, 1988
  • Super Doctor SuperDoctors.com
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone As Salvage Therapy in Relapsed/Refractory Multiple Myeloma: Results of a Sa...
    Edward D. Ball, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone As Salvage Therapy in Relapsed/Refractory Multiple Myeloma: Results of a Sa...
    Edward D. Ball, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Other

  •  
    Gschwend TA, Tumorimmunology, Department of Clinical Research, University of Bern
    1/1/2013

Press Mentions

  • UCSD Offers New Immunotherapy for Types of Non-Hodgkin Lymphoma
    UCSD Offers New Immunotherapy for Types of Non-Hodgkin LymphomaDecember 3rd, 2018